|
Lani,
If you meant to include a link to the Sweden study in your post, it is missing.
Standardized testing (or the lack thereof) has been an issue for not just Her2 but other prognostic factors, as well, leading to uncertainty about the true prevalance of Her2+ bc. What will be enlightening, IMO, will be the results following the application of more accurate methods and uniform testing standards on a going-forward basis.
Hopeful
|